Journal
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION
Volume 9, Issue 1, Pages 48-53Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jash.2014.11.001
Keywords
Canagliflozin; dapaglifiozin; empagliflozin; hypertension
Categories
Ask authors/readers for more resources
The sodium glucose co-transporter 2 (SGLT2) inhibitors represent a promising treatment option for diabetes and its common comorbidity, hypertension. Emerging data suggests that the SGLT2 inhibitors provide a meaningful reduction in blood pressure, although the precise mechanism of the blood pressure drop remains incompletely elucidated. Based on current data, the blood pressure reduction is partially due to a combination of diuresis, nephron remodeling, reduction in arterial stiffness, and weight loss. While current trials are underway focusing on cardiovascular endpoints, the SGLT2 inhibitors present a novel treatment modality for diabetes and its associated hypertension as well as an opportunity to elucidate the pathophysiology of hypertension in diabetes. (C) 2015 American Society of Hypertension. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available